A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients
Status:
Active, not recruiting
Trial end date:
2022-06-14
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and efficacy of ASC22 in the treatment
of chronic hepatitis B after single and multiple drug administration.
Phase:
Phase 2
Details
Lead Sponsor:
Ascletis Pharmaceuticals Co., Ltd.
Collaborators:
Beijing Clinical Service Center Peking University First Hospital